Central Nervous System (CNS)

Lacovimp

Indication:

  • FDA (focal epilepsy as monotherapy and as adjunctive therapy).
  • EMEA (focal epilepsy with or without secondary generalized as mono therapy and as adjunctive therapy).

 

How it works:

Lacovimp has unique dual MOA:

  1. Modulation of the slow inactivation of VGSC.
  2. Modulation of Collapsing response mediator protein 2 -mediated neurotrophic signals.

 

How to use:

For Adult:
As monotherapy 100 mg twice daily for further control, add 50 mg twice daily on weekly interval to max 400 mg /day
As add on 50 mg twice daily for further control add 50 mg twice daily on weekly interval to max 400 mg /day

2. For Pediatric:
Children weight 50 kg use 50 mg twice daily for further control add 50 mg twice daily on weekly interval to max 400 mg /day in case of monotherapy or combination.

 

Active Ingredient Function Concentration

Lacosamide

Lacosamide 50 mg and 100 mg